Radioreceptor assay for serum levels of cetamolol, a new β-adrenoceptor antagonist

1984 ◽  
Vol 17 (3) ◽  
pp. 162-165 ◽  
Author(s):  
Michael D. Stern
Keyword(s):  
Serum Levels ◽  
Radioreceptor Assay ◽  
Adrenoceptor Antagonist

Effects of glucocorticoid on body growth and serum levels of somatomedin A in the rat

1982 ◽  
Vol 100 (2) ◽  
pp. 206-210 ◽  
Author(s):  
Kumiko Asakawa ◽  
Kazue Takano ◽  
Megumi Kogawa ◽  
Yoko Hasumi ◽  
Kazuo Shizume
Keyword(s):  
Growth Rate ◽  
Body Weight ◽  
Weight Gain ◽  
Body Weight Gain ◽  
Serum Levels ◽  
Radioreceptor Assay ◽  
Body Growth ◽  
Cortisone Acetate ◽  
Combined Administration ◽  
A Minor

Abstract. Serum levels of somatomedin A, as measured by radioreceptor assay, and body weight gain were 86.5 ± 9.2% and 166.9 ± 7.8% (N = 5) of the initial values, respectively, after 18 days administration of 2.5 mg cortisone acetate (CA). These values were significantly lower than those for saline treated rats (P < 0.005). Reduced serum somatomedin A and body growth rate were partially restored after halting the injection of CA. Combined administration of daily doses of 100 μg hGH with CA did not prevent the decrease in somatomedin activity in treated rats. This observation suggests that GH plays a minor (or no) role in the fall of serum somatomedin A in CA-treated rats. From these data we conclude that glucocorticoids reduce serum somatomedin by inhibiting the effect of GH on the generation of somatomedin.

Somatomedin A levels in patients with Cushing's disease

1981 ◽  
Vol 97 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Marja Thorén ◽  
Kerstin Hall ◽  
Tiit Rähn
Keyword(s):  
Direct Effect ◽  
Cushing’S Disease ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Significant Rise ◽  
Radioreceptor Assay ◽  
Cushing's Disease ◽  
Stereotactic Radiation ◽  
Retarding Effect ◽  
Selective Impairment

Abstract. The serum levels of immunoreactive somatomedin A (SMA) in 23 patients with Cushing's disease, aged 6–61 years, were within the range of healthy subjects for their ages. No correlation was found between SMA and the excretion of cortisol. After im administration of hGH (8 IU = 4 mg) daily for 3 days there was a significant rise in SMA, both determined by radioimmunoassay and radioreceptor assay. Thus no impairment was found in the GH-dependent SMA levels or the ability of hGH to generate somatomedin, which indicates that the growth retarding effect of cortisol is most likely due to a direct effect on the tissue. After treatment with stereotactic radiation to the hypophysis there was a significant decrease in cortisol excretion without any change in SMA levels, indicating the possibility to achieve a selective impairment of the ACTH-cortisol axis.

scholarly journals Metoprolol Reduces Proinflammatory Cytokines and Atherosclerosis in ApoE−/−Mice

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Marcus A. Ulleryd ◽  
Evelina Bernberg ◽  
Li Jin Yang ◽  
Göran M. L. Bergström ◽  
Maria E. Johansson
Keyword(s):  
Total Cholesterol ◽  
Thoracic Aorta ◽  
Atherosclerotic Plaque ◽  
Proinflammatory Cytokines ◽  
Serum Levels ◽  
Adrenoceptor Antagonist ◽  
Plaque Area ◽  
Cholesterol Levels ◽  
Antiatherosclerotic Effect ◽  
Inflammatory Effect

A few studies in animals and humans suggest that metoprolol (β1-selective adrenoceptor antagonist) may have a direct antiatherosclerotic effect. However, the mechanism behind this protective effect has not been established. The aim of the present study was to evaluate the effect of metoprolol on development of atherosclerosis in ApoE−/−mice and investigate its effect on the release of proinflammatory cytokines. Male ApoE−/−mice were treated with metoprolol (2.5 mg/kg/h) or saline for 11 weeks via osmotic minipumps. Atherosclerosis was assessed in thoracic aorta and aortic root. Total cholesterol levels and Th1/Th2 cytokines were analyzed in serum and macrophage content in lesions by immunohistochemistry. Metoprolol significantly reduced atherosclerotic plaque area in thoracic aorta (P<0.05versus Control). Further, metoprolol reduced serum TNFαand the chemokine CXCL1 (P<0.01versus Control for both) as well as decreasing the macrophage content in the plaques (P<0.01versus Control). Total cholesterol levels were not affected. In this study we found that a moderate dose of metoprolol significantly reduced atherosclerotic plaque area in thoracic aorta of ApoE−/−mice. Metoprolol also decreased serum levels of proinflammatory cytokines TNFαand CXCL1 and macrophage content in the plaques, showing that metoprolol has an anti-inflammatory effect.

Neuroleptic Serum Levels Measured by Radioreceptor Assay in Patients Receiving Intramuscular Depot Neuroleptics Some Preliminary Findings

1985 ◽  
Vol 146 (4) ◽  
pp. 439-442 ◽  
Author(s):  
John Turbott ◽  
John Villiger ◽  
Lynley Hunter
Keyword(s):  
Blood Level ◽  
Serum Levels ◽  
Radioreceptor Assay ◽  
Time Interval ◽  
Fluphenazine Decanoate ◽  
Wide Range ◽  
Schizophrenic Patients ◽  
Depot Neuroleptic ◽  
Flupenthixol Decanoate ◽  
Inter Assay Variation

SummaryTwenty-six chronic schizophrenic patients on well established depot neuroleptic regimes with stable doses (16 on fluphenazine decanoate, ten on flupenthixol decanoate) had serum neuroleptic levels measured by a radioreceptor assay (RRA) method. The assay was sufficiently sensitive to measure serum levels in all cases, with acceptable levels of inter-assay variation. Blood level measurements were repeated on two occasions, at the same time interval from the last injection, in 18 patients (11 on fluphenazine decanoate, seven on flupenthixol decanoate) and remained reasonably stable in most cases, although others showed a wider variation. Despite a wide range of doses (× 32 fluphenazine decanoate, × 21 flupenthixol decanoate) the serum levels fell in a remarkably narrow range (× 4, × 6). There was a significant correlation between dose and blood level for flupenthixol decanoate, but not for fluphenazine decanoate.

Neuroleptic Serum Levels Measured by Radioreceptor Assay and Clinical Response in Schizophrenic Patients

1981 ◽  
Vol 169 (1) ◽  
pp. 60-63 ◽  
Author(s):  
LARRY E. TUNE ◽  
IAN CREESE ◽  
J. RAYMOND DEPAULO ◽  
PHILLIP R. SLAVNEY ◽  
SOLOMON H. SNYDER
Keyword(s):  
Clinical Response ◽  
Serum Levels ◽  
Radioreceptor Assay ◽  
Schizophrenic Patients

Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations

1979 ◽  
Vol 1 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Helena M. Calil ◽  
David H. Avery ◽  
Leo E. Hollister ◽  
Ian Creese ◽  
Solomon H. Snyder
Keyword(s):  
Serum Levels ◽  
Radioreceptor Assay ◽  
Clinical Observations

Depot Neuroleptic Medication and Serum Levels by Radioreceptor Assay: Prolactin Concentration, Electrocardiogram Abnormalities and Six-Month Outcome

1987 ◽  
Vol 21 (3) ◽  
pp. 327-338
Author(s):  
John Turbott ◽  
John Villiger ◽  
Lynley Hunter
Keyword(s):  
Serum Levels ◽  
Radioreceptor Assay ◽  
Clinical State ◽  
Serum Prolactin ◽  
Chronic Patients ◽  
Fluphenazine Decanoate ◽  
Schizophrenic Patients ◽  
Depot Neuroleptic ◽  
Electrocardiogram Ecg ◽  
Flupenthixol Decanoate

Twenty-six chronic schizophrenic patients on well-established depot neuroleptic regimes with stable doses (16 on fluphenazine decanoate, 10 on flupenthixol decanoate) had serum neuroleptic levels measured by radioreceptor assay (RRA) and were followed for six months. The serum prolactin (PRL) concentration and resting electrocardiogram (ECG) were also taken at the beginning of the study period. Correlations had previously been noted between RRA measured neuroleptic levels and outcome in both acute and chronic patients on oral medication. However, in this study of depot medication no significant correlations were found between serum neuroleptic concentration, serum prolactin concentration and the clinical state or outcome. The prevalence (33%) and type of ECG abnormality observed was similar to that previously reported.

GROWTH IMPAIRMENT WITH ELEVATED SOMATOMEDIN LEVELS IN CHILDREN WITH CHRONIC RENAL INSUFFICIENCY

1979 ◽  
Vol 91 (1) ◽  
pp. 36-48 ◽  
Author(s):  
E. Martin Spencer ◽  
K. O. Uthne ◽  
W. C. Arnold
Keyword(s):  
Renal Function ◽  
Renal Insufficiency ◽  
Chronic Renal Insufficiency ◽  
Growth Failure ◽  
Normal Growth ◽  
Serum Levels ◽  
Radioreceptor Assay ◽  
Growth Impairment ◽  
Successful Transplantation

ABSTRACT In children with chronic renal insufficiency serum levels of somatomedin measured by radioreceptor assay were found to be strikingly elevated and were in the same range as in acromegaly in spite of decreased growth. The serum somatomedin level was inversely correlated with renal function and children on haemodialysis had the highest values. The elevated somatomedin was most likely due to progressive destruction of the kidney, the primary catabolic site for somatomedin and other polypeptides. After successful transplantation the somatomedin values fell to slightly above normal even though growth was still impaired. Using a bioassay based on the mitogenic property of somatomedin, a lower than normal rather than an increased level was found in chronic renal insufficiency suggesting that in uraemia an inhibitor to somatomedin bioactivity was present. It is concluded that the cause of the growth failure in chronic renal insufficiency and after transplantation is not due to a lack of somatomedin, but an inhibitor to its action could be a factor. It would appear that a normal somatomedin may be necessary for normal growth, but it is not sufficient.

Nucleolar Segregation and Chronic Methanol Intoxication

1969 ◽  
Vol 27 ◽  
pp. 360-361
Author(s):  
Julio H. Garcia ◽  
Janice P. Van Zandt
Keyword(s):  
Body Weight ◽  
Methyl Alcohol ◽  
Rhesus Monkeys ◽  
Repeated Administration ◽  
Serum Levels ◽  
Methanol Intoxication ◽  
Intragastric Tube ◽  
Nucleolar Segregation

Repeated administration of methyl alcohol to Rhesus monkeys (Maccaca mulata) by intragastric tube resulted in ultrastructural abnormalities of hepatocytes, which persisted in one animal twelve weeks after discontinuation of the methyl alcohol regime. With dosages ranging between 3.0 to 6.0 gms. of methanol per kg. of body weight, the serum levels attained within a few hours averaged approximately 475 mg. per cent.

Sign in / Sign up

Export Citation Format

Share Document